Otsuka Pharmaceutical Factory and Fresenius Kabi Japan enter into an exclusive distribution agreement of HES products, including the newly approved Voluven 6%

Otsuka Pharmaceutical Factory, Inc.  and Fresenius Kabi Japan (FKJ) have entered into an exclusive distribution agreement in Japan, of Voluven 6%, a new to be launched HES (Hydroxyethl Starch) product, (approved on March 25, 2013) and two other existing HES products, Salinhes Fluid Solution 6% and Hespander Fluid Solution. The two products on the market are currently sold by FKJ.